Korean J Gastroenterol.  2022 Apr;79(4):156-160. 10.4166/kjg.2022.049.

Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B

• Hong YM
• Yoon KT

• KMID: 2529365
• DOI: http://doi.org/10.4166/kjg.2022.049

Abstract

In the natural course of chronic hepatitis B, the immune tolerance phase is characterized by HBeAg positivity, very high levels of HBV DNA, and persistent normal alanine aminotransferase. The international guideline recommendation for patients in this phase is observation without antiviral treatment because of the low risk of disease progression and the lack of effective antiviral agents. However, recent retrospective studies have shown that progression to hepatic fibrosis and hepatocellular carcinoma may occur in patients who are in the immune tolerance phase. Despite the conceptual definition and clinical diagnostic criteria for this phase, it is difficult to accurately diagnose the true immune tolerance phase. Therefore, we should pay attention to the clinical evaluation and interpretation of the immune tolerance phase and understand the clinical situations in which antiviral treatments should be considered.

Keyword

Hepatitis B; chronic; Immune tolerance

Reference

1. Korean Association for the Study of the Liver (KASL). 2019; KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 25:93–159. DOI: 10.3350/cmh.2019.1002. PMID: 31185710. PMCID: PMC6589848.

2. Terrault NA, Lok ASF, McMahon BJ, et al. 2018; Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–1599. DOI: 10.1002/hep.29800. PMID: 29405329. PMCID: PMC5975958.

3. European Association for the Study of the Liver. 2017; EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398. DOI: 10.1016/j.jhep.2017.03.021. PMID: 28427875.

4. Sarin SK, Kumar M, Lau GK, et al. 2016; Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 10:1–98. DOI: 10.1007/s12072-015-9675-4. PMID: 26563120. PMCID: PMC4722087.

5. Park JY, Park YN, Kim DY, et al. 2008; High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 15:615–621. DOI: 10.1111/j.1365-2893.2008.00989.x. PMID: 18573162.

6. Kim GA, Lim YS, Han S, et al. 2018; High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 67:945–952. DOI: 10.1136/gutjnl-2017-314904. PMID: 29055908.

7. Lee HA, Lee HW, Kim IH, et al. 2020; Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 52:196–204. DOI: 10.1111/apt.15741. PMID: 32452564.

8. Kennedy PTF, Sandalova E, Jo J, et al. 2012; Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 143:637–645. DOI: 10.1053/j.gastro.2012.06.009. PMID: 22710188.

9. Sinn DH, Lee JH, Kim K, et al. 2017; A novel model for predicting hepatocellular carcinoma development in patients with chronic hepatitis B and normal alanine aminotransferase levels. Gut Liver. 11:528–534. DOI: 10.5009/gnl16403. PMID: 27980231. PMCID: PMC5491088.

10. Shim JJ, Kim JW, Oh CH, et al. 2018; Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B: a large national cohort study. Liver Int. 38:1751–1759. DOI: 10.1111/liv.13705. PMID: 29377574.

11. Wong GL, Wong VW, Choi PC, et al. 2009; Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol. 7:227–233. DOI: 10.1016/j.cgh.2008.10.023. PMID: 19121647.

12. Wai CT, Greenson JK, Fontana RJ, et al. 2003; A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 38:518–526. DOI: 10.1053/jhep.2003.50346. PMID: 12883497.

13. Vallet-Pichard A, Mallet V, Nalpas B, et al. 2007; FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 46:32–36. DOI: 10.1002/hep.21669. PMID: 17567829.

14. Wong GL. 2013; Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf). 1:19–26. DOI: 10.1093/gastro/got007. PMID: 24759663. PMCID: PMC3941434.

15. Chon YE, Choi EH, Song KJ, et al. 2012; Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 7:e44930. DOI: 10.1371/journal.pone.0044930. PMID: 23049764. PMCID: PMC3458028.

16. Hui CK, Leung N, Yuen ST, et al. 2007; Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 46:395–401. DOI: 10.1002/hep.21724. PMID: 17628874.

17. Rosenthal P, Ling SC, Belle SH, et al. 2019; Combination of entecavir/peginterferon Alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection. Hepatology. 69:2326–2337. DOI: 10.1002/hep.30312. PMID: 30318613. PMCID: PMC6465180.

18. Chan HL, Chan CK, Hui AJ, et al. 2014; Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 146:1240–1248. DOI: 10.1053/j.gastro.2014.01.044. PMID: 24462735.

19. Wong VW, Hui AJ, Wong GL, et al. 2018; Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients. J Clin Gastroenterol. 52:347–352. DOI: 10.1097/MCG.0000000000000852. PMID: 28723855.

20. Chang Y, Choe WH, Sinn DH, et al. 2017; Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: a nationwide, multicenter, retrospective study. J Infect Dis. 216:1407–1414. DOI: 10.1093/infdis/jix506. PMID: 29029102.

21. Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. 2021; Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut. 70:2172–2182. DOI: 10.1136/gutjnl-2020-321309. PMID: 33239344.

22. Liu CP, Zeng YL, Zhou M, et al. 2015; Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis. Intern Med. 54:711–716. DOI: 10.2169/internalmedicine.54.3514. PMID: 25832930.

23. Wen WH, Chang MH, Zhao LL, et al. 2013; Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 59:24–30. DOI: 10.1016/j.jhep.2013.02.015. PMID: 23485519.

24. Lee YS, Lee HS, Kim JH, et al. 2021; Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. Korean J Intern Med. 36:76–85. DOI: 10.3904/kjim.2018.465. PMID: 31878771. PMCID: PMC7820648.